Yescas-Osorio IN, Razo-Solano R, Ávila-Esquivel JF, Cejudo-Álvarez J, Elizalde-Valdés VM, Herrera-Villalobos JE, Hernández-Valencia M

Language: Spanish
References: 18
Page: 347-354
PDF size: 406.19 Kb.

ABSTRACT

Backgroun: Severe preeclampsia as a public health problem is a multifactorial and several events that result in highly lethal episodes of obstetric emergencies. In Mexico according to data reported by the INEGI, preeclampsia had a frequency until 35.6%. Maternal death is an indicator of impact and quality of obstetric care and is associated with failures in the health care and preventable deaths are up 80%. Prevention is most important to prevent complications, as well biochemical markers as risk factors like uric acid to known is modified levels in this obstetric complication.
Objetives: To determine whether serum uric acid levels correlate with the presence of severe preeclampsia, as well as their clinical presentation, and maternal morbidity and fetal mortality in patients hospitalized in the intensive care unit.
Material and Methods: A cross-sectional study, retrolective, descriptive was carried-out. Were included pregnancies higher than 20 weeks with reports of serum measurement of uric acid at hospitalization, with an established diagnosis of severe preeclampsia were admitted to the service of intensive care unit. Statistical analysis was performed using Microsoft Excel 2010 and the Statistical program SPSS for Windows version 19.0.
Results: Were included 72 patients in the present study, pregnant normotensive patients had significantly lower uric acid 3.6±0.4 mg/dL compared with the study group with severe preeclampsia 6.3±1.4 mg/dL (p ‹0.001). With regard to the clinical manifestation the vasospasm and the epigastralgia were related with the hyperuricemia; as well as the studied data of severity, as the acute renal damage with the consequent direct correspondence in the maternal mortality. In relation to the fetal pronostic a negative correlation is observed in the qualification APGAR with more importance to the 5 minutes.
Conclusions: In this study, a statistically significant relationship between high levels of uric acid in the presence of preeclampsia was identified. With respect to the clinical presentation of data presentation and epigastralgia vasospasm they are related to hyperuricemia, and is associated with poor perinatal and maternal outcomes. Thus, the elevation of uric acid could be a prognostic tool for easy determination that would identify a group of patients with severe preeclampsia associated with higher damage.

REFERENCES

1. World Health Organization. WHO Recomendaciones de la prevención y tratamiento de la preeclampsia y la eclampsia. Organización Mundial de la Salud 2011. WHO/HRH/11.30.

2. SINA VE/DGE/Salud/Sistema de Muertes Maternas/Información al 26 de Agosto 2012-2013.

3. Observatorio de Mortalidad Materna en México: www. omm.org.mx

4. Guía de Práctica Clínica. Atención integral de Preeclampsia en el segundo y tercer concentraciónes de atención. México: Secretaría de Salud; 2008.

5. Valencia OJ, Zárate A, Saucedo R, Hernández- Valencia M, Cruz-Durán JG, Puello-Tamara E, Arechavaleta-Velasco F. Implicaciones clínicas de la investigación básica de la preeclampsia: tolerancia inmunológica. Ginecol Obstet Mex 2015;83:505-514.

6. Llanes MR, Tuuli MG, Rampersad R, Stamilo D. Perinatal outcomes inwomen with preeclampsia and superimposed preeclampsia: do they differ?. Am J Obstet Gynecol 2011;204:508-510.

7. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25:391-394.

8. Backes CH, Markham K, Moorehead P, Cordero L, Nankervis CA, Giannone PJ. Maternal preeclampsia and neonatal outcomes. J Pregnancy 2011;2011:1-7.

9. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010;5: 173-192.

10. Laughon SK, Catov J. First trimester uric acid and adverse pregnancy outcomes. Am J Hypertens 2011;24:489-495.

11. Johnson RK, Kanbay M. Uric acid: A clinically useful marker to distinguish preeclampsia from gestacional hypertension. 2011;58:548-549.

12. Alcalino H, Greig D, Castro P, Verdejo H, Mellado R, García L, Díaz-Araya G, Quiroga C, Chiong M, Lavandero S. Ácido úrico: una molécula con acciones paradójicas en la insuficiencia cardiaca. Rev med Chile 2011;139:505-515.

13. Hawkins TL, Roberts JM, Mangos GJ, Davis GK, Roberts LM, Brown MA. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: a retrospective cohort study. BJOG 2012; 119: 484-492.

14. Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta 2008; 29: S67-72.

15. Levin SK, Catov J, Powers RW, Roberts JM, Gandley RE. First trimester uric acid and adverse pregnancy outcomes. Am J Hypertens 2011; 24: 489-495.

16. Main EK. Maternal mortality: new strategies for measurement and prevention. Curr Opin Obstet Gynecol 2010; 22:511-513.

17. Reyna-Villasmil E. Concentraciones de ácido úrico en pacientes con preeclampsia y eclampsia. Clin Invest Gin Obst. 2008;35:160-165.

18. Abalos E, Cuesta C, Grosso AL. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170:1-8.